血糖控制仍是2型糖尿病管理优先层级中的核心
本文由初级保健与糖尿病专家小组通过聚焦文献检索,重新评估血糖控制在2型糖尿病管理中的地位。文章回顾从强化血糖控制试验到心血管结局试验(CVOTs)的证据演变,指出CVOTs结果主要来自合并心血管/肾脏疾病或多种危险因素者,而早期诊断的高危人群多无并发症,早期良好控制血糖与心血管代谢危险因素具有 legacy 效应,可减少心血管和肾脏事件及全因死亡。鉴于缺乏强化血糖控制与新型降糖药器官保护作用协同效应的RCT,文章强调将血糖控制作为多数2型糖尿病患者早期关键治疗目标,同时针对现有心血管和肾脏疾病,并提倡多学科多因素管理。
要点
- 早期和强化血糖控制是降低2型糖尿病长期不良结局风险的核心策略。
- CVOTs显示的器官保护作用主要来自合并心血管/肾脏疾病或多种危险因素的人群。
- 早期良好控制血糖和心血管代谢危险因素具有 legacy 效应,可减少心血管和肾脏事件及全因死亡。
核心结论
- 文章重新评估科学证据演变,强调将血糖控制作为多数2型糖尿病患者早期关键治疗目标的重要性,同时针对现有心血管和肾脏疾病。
- 文章强调采用多学科方法实施多因素管理,以促进定期评估、患者赋权和根据2型糖尿病异质性量身定制干预的可能性。
研究设计与样本
- 由初级保健和糖尿病专家组成的小组进行聚焦文献检索,回顾血糖控制在2型糖尿病管理中当前作用的证据。
主要发现
- CVOTs结果主要来自合并既往心血管和肾脏疾病或多种危险因素的2型糖尿病患者。
- 近年来高危个体更早诊断,使大部分2型糖尿病患者无并发症。
- 在这些个体中,早期和最佳控制血糖及心血管代谢危险因素的 legacy 效应已被证明可减少心血管和肾脏疾病事件及全因死亡。
- 缺乏研究强化血糖控制与新型降糖药器官保护作用潜在协同效应的RCT。
局限性
- 缺乏研究强化血糖控制与新型降糖药器官保护作用潜在协同效应的RCT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A panel of primary care and diabetes specialists conducted focused literature searches on the current role of glycaemic control in the management of type 2 diabetes and revisited the evolution of evidence supporting the importance of early and intensive blood glucose control as a central strategy to reduce the risk of adverse long-term outcomes. The optimal approach to type 2 diabetes management has evolved over time as the evidence base has expanded from data from trials that established the role of optimising glycaemic control to recent data from cardiovascular outcomes trials (CVOTs) demonstrating organ-protective effects of newer glucose-lowering drugs (GLDs). The results from these CVOTs were derived mainly from people with type 2 diabetes and prior cardiovascular and kidney disease or multiple risk factors. In more recent years, earlier diagnosis in high-risk individuals has contributed to the large proportion of people with type 2 diabetes who do not have complications. In these individuals, a legacy effect of early and optimal control of blood glucose and cardiometabolic risk factors has been proven to reduce cardiovascular and kidney disease events and all-cause mortality. As there is a lack of RCTs investigating the potential synergistic effects of intensive glucose control and organ-protective effects of newer GLDs, this article re-evaluates the evolution of the scientific evidence and highlights the importance of integrating glycaemic control as a pivotal early therapeutic goal in most people with type 2 diabetes, while targeting existing cardiovascular and kidney disease. We also emphasise the importance of implementing multifactorial management using a multidisciplinary approach to facilitate regular review, patient empowerment and the possibility of tailoring interventions to account for the heterogeneity of type 2 diabetes.
引用
- Khunti K, Zaccardi F, Amod A, et al. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management. Diabetologia. 2024. PMID: 39155282. doi:10.1007/s00125-024-06254-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。